Homepage ACN Newswire newsroom

Frost & Sullivan report identifies PromarkerD as the world leading test for Diabetic Kidney Disease

Announcement posted by ACN Newswire 29 Mar 2017

PERTH, W. AUSTRALIA, Mar 28, 2017 - (ACN Newswire) - Proteomics International Laboratories Ltd (PILL; ASX:PIQ) is the leader in predictive diagnostics for diabetic kidney disease, according to an independent Frost & Sullivan report released this month. PILL managing director Dr Richard Lipscombe is in Shanghai this week meeting with possible commercialisation partners for China, and was showcasing PromarkerD at the China-Australia Biotech Investment forum in Shanghai today.

Dr Lipscombe said the new report, titled Biomarkers Enabling Diabetes and Obesity Management, identifies PromarkerD as the world leader. The report says novel biomarker research is likely to transform the future of obesity and diabetes management. 

Frost & Sullivan states that novel tools like PromarkerD can allow enhanced management of obesity, diabetes and related complications in the near future, and goes on to highlight PILL's novel test for diabetic kidney disease noting its high adoption potential.[1]

PromarkerD technology has also been validated by the peer-reviewed scientific journal EuPA Open Proteomics, the official journal of the European Proteomics Association (EuPA).[2]

There is currently no available test for predicting the onset of diabetic kidney disease and Frost & Sullivan suggest PILL is one of only two companies worldwide developing such a test. Results have shown PromarkerD can correctly predict 95% of previously kidney disease-free diabetic patients who go on to develop chronic kidney disease.

PILL already has a deal in place with Chinese biopharmaceutical company Newsummit Biopharma Co. (NSB) to manufacture the PromarkerD kit in China. The process includes engagement of Key Opinion Leaders and Hospitals, who will facilitate validation of the completed kit.

Publication details
[1] 'Biomarkers Enabling Diabetes and Obesity Management' published by Frost & Sullivan, March 2, 2017.
[2] 'Comprehensive Mass Spectrometry Based Biomarker Discovery and Validation Platform as Applied to Diabetic Kidney Disease' published in EuPA Open Proteomics, the official journal of the European Proteomics Association, March 1, 2017.
*Materials available at http://bit.ly/2nqMfNY

Multimedia
Presentation: An audio summary of the research paper.
Video: The power of the Promarker platform for personalised medicine. 
*MultiMedia available at http://bit.ly/2nqMfNY

PromarkerD: a predictive diagnostic test for diabetic kidney disease --

The EuPA article followed an evaluation by independent experts, and verifies the process used to develop and test PILL's PromarkerD protein 'fingerprint'. This novel test can both diagnose and predict disease. In diabetics already suffering from chronic kidney disease, PromarkerD diagnosed disease missed by current gold standard tests, known as the ACR and eGFR tests. 

Critically, PromarkerD can also predict the onset of disease before clinical symptoms appear. In an extension of the published work 576 patients were followed in a four-year longitudinal clinical study. PromarkerD correctly predicted 95% of the previously kidney disease-free diabetic patients who went on to develop chronic kidney disease. 

About the Promarker Platform --

PILL's diagnostic research is made possible by the company's proprietary biomarker discovery platform termed Promarker, which searches for protein 'fingerprints' in a sample. This disruptive technology can identify proteins that distinguish between people who have a disease and people who do not, using only a simple blood test. It is a powerful alternative to genetic testing.

About Proteomics International Laboratories (PILL) --

PILL (ASX: PIQ) is a medical technology company focused on proteomics - the industrial scale study of the structure and function of proteins - and is recognised as a global leader in the field. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the-art facilities at the Harry Perkins Institute of Medical Research in Perth, Western Australia.

For further information, please visit www.proteomics.com.au, or contact:

Dr Richard Lipscombe
Managing Director,
Proteomics International Laboratories Ltd
E: enquiries@proteomics.com.au
T: +61 2 8218 2144

Media Contact:
Susan Fitzpatrick-Napier
Digital Mantra Group
E: team@dmgpr.com
T: +61 8 9389 1992